Home
About
Capabilities
R&D
Investors
News
Careers
中文
Home
About
Capabilities
R & D
Investors
News
Careers
Press Release
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
Dec 30, 2021
Mabwell Announced the First Person Dosed in the Phase I Study of First Anti-ST2 Antibody in China
➞
Dec 30, 2021
Honorary Qualification | Mabwell awarded as "Excellent Case" of Shanghai Industrial Talent Team Construction 2021
➞
Dec 22, 2021
The New Drug Application of Mabwell's Denosumab Injection Biosimilars 9MW0311 Was Accepted
➞
Dec 22, 2021
The New Drug Application of Mabwell's Denosumab Injection Biosimilars 9MW0321 Was Accepted
➞
Oct 21, 2021
Facilitate Development and Accelerate Progress | Shanghai OPCSTIC Visit Mabwell Bioscience to Research and Guide Work
➞
Oct 19, 2021
China's First Anti-Nectin-4 ADC Drug Receives IND Approval
➞
Oct 13, 2021
Honorary Qualification│Mabwell awarded the BIGStar 2021 Chinese Most Promising Innovative Biopharmaceutical Enterprises
➞
Sep 27, 2021
Mabwell Announced the First Patient Dosed in the Phase I Study of CD47/PD-L1 Bispecific Antibody
➞
Sep 22, 2021
Leaders of Shanghai Development and Reform Commission, Shanghai Municipal Commission of Economy and Informatization Technology and Finance Bureau of Shanghai make an on-site investigation to Mabwell
➞
Sep 17, 2021
Strive to Strengthen the Innovation Engine and Create a New Highland of Independent Innovation! Hang Yingwei, Director of Pudong New Area, and his team went to Mabwell for Investigation & Research
➞
1
2
3
下一页